Novartis Pharmaceuticals is conducting a phase two, multicentered, randomized, open label study to look at the safety and efficacy of using eltrombopag in combination with short-term pulse high dose of dexamethasone therapy in adult ITP patients who are newly diagnosed. The aim of the study is to compare the effectiveness of using this treatment approach compared to short-term high dose dexamethasone monotherapy alone as a first line treatment in this ITP patient population. Participants must be at least 18 years of age, and must have a platelet count less than 30 x 109/L.
Germany
https://clinicaltrials.gov/ct2/show/NCT04346654?recrs=a&cond=Immune+Thrombocytopenia&draw=2&rank=24
Recruiting
